25% Off Cancer Antibodies
Biopharmaceuticals require products to be free of host cell protein (HCP) contaminants. These HCPs may be left behind during the purification process from the expression hosts, such as E. coli, insect, or mammalian cells. To investigate the presence of residual contamination during the bioprocessing and the final biopharmaceutical product, development of custom polyclonal antibody reagents with maximum coverage against native HCP extracts is required. Please see US FDA Guidelines for Bioanalytical Validation. Rockland provides multiple customizable options for HCP antibody development. These options allow flexibility to the researcher to develop early stage through late stage HCP detection reagents.
Rockland and The Scientist brought together a panel of experts to highlight some of the exciting areas where precision medicine is pushing the boundaries of science, technology, and therapy.Topics covered:• Tools and techniques for studying genetic variation• Challenges in data analysis• Application of genetic information to the development of targeted therapiesWith speakers, Dr. Geoffrey Ginsburg, Director of Center for Applied Genomics & Precision Medicine and Dr. Elizabeth Worthey Faculty Investigator and Director of Bioinformatics.
2D-SDS PAGE Analysis Methods For Determining HCP Coverage Using Process Derived anti-HCP Polyclonal Antibodies
Production and Characterization of High Coverage, Process Specific Pichia P. HCP Antibodies
Download the Multi-assay Functional Antibodies in HCP Detection poster
Download the Enhanced Standardized HCP poster
Producing an HCP Antibody: Workflow
Rockland Immunochemicals Inc.Limerick, PA 19468E-mail: firstname.lastname@example.orgPhone: 800.656.7625